Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Phanes Therapeutics, Inc.Startup |
Active Organization Phanes Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Epithelial Carcinoma | Preclinical | - | Phanes Therapeutics, Inc.Startup | - |